Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.
- A$100,000+ GST contract with Imunexus Therapeutics
- TrialKey platform applied to clinical trial optimisation and capital raising support
- Initial payment plus milestone-based fees contingent on Imunexus capital raises
- Contract term of one year with potential for expanded future engagements
- Validates Pathkey’s commercialisation strategy and AI technology adoption
A Milestone Commercial Win
Pathkey.AI Ltd (ASX:PKY), an Australian artificial intelligence company specialising in biotechnology applications, has announced a key commercial contract with Imunexus Therapeutics Limited. Valued at up to A$100,000 plus GST, this agreement marks the largest engagement secured by Pathkey to date and signals growing market acceptance of its TrialKey platform.
The contract, effective from 1 April 2026, involves deploying TrialKey to support Imunexus’s early-phase clinical trial design and preparation for future capital raising. An initial payment of A$25,000 plus GST was made upon execution, with the remaining A$75,000 contingent on Imunexus achieving certain capital raising milestones.
TrialKey in Action
TrialKey is an AI-powered decision-support system designed to predict the probability of success and optimise clinical trial protocols. For Imunexus, a biotechnology company focused on novel immunotherapies for neuroinflammatory diseases such as multiple sclerosis, the platform will integrate pipeline assets, deliver baseline analytics, and refine clinical protocols. This phased approach not only supports immediate clinical development needs but also aligns with Imunexus’s capital markets strategy.
Pathkey’s technology combines machine learning, large language models, and reasoning systems to transform complex, unstructured data into actionable insights. By embedding TrialKey into Imunexus’s workflows, the biotech firm gains a data-driven edge in both scientific and investment decision-making.
Strategic Implications and Growth Potential
Executive Director Damon Rasheed highlighted the significance of the deal, stating it validates Pathkey’s ability to convert its AI capabilities into tangible revenue. The contract also positions Pathkey for follow-on work and expanded engagements, as demand grows for technologies that improve trial efficiency and reduce development risk.
With the global clinical development sector expanding rapidly, Pathkey’s platform addresses a critical need for predictive analytics in drug development and capital raising. This engagement with Imunexus demonstrates a repeatable commercial model that could be replicated across pharmaceutical, biotechnology, and advisory clients.
While a portion of the contract value depends on Imunexus’s future capital raising success, the initial phase provides immediate revenue and a foundation for ongoing collaboration. Pathkey’s ability to integrate into both scientific and capital markets workflows broadens its potential customer base and strengthens its commercial pipeline.
Looking Ahead
As Pathkey continues to build momentum, this contract serves as a tangible milestone in its commercialisation journey. The company’s focus on AI-driven solutions for complex, data-intensive industries positions it well to capitalise on the growing intersection of biotechnology and artificial intelligence.
Bottom Line?
Pathkey’s latest contract not only delivers immediate revenue but also sets the stage for broader adoption of AI in clinical development and capital markets.
Questions in the middle?
- Will Imunexus successfully complete the capital raising milestones to unlock full contract value?
- How quickly can Pathkey replicate this commercial model with other biotech clients?
- What competitive advantages does TrialKey hold against other AI platforms in clinical trial optimisation?